Decitabine as “bridge therapy” to a MUD transplant in relapsed AML postautologous stem cell transplantation

Abstract

Listen

Translate article

American Journal of HematologyVolume 83, Issue 10 p. 825-827 LetterFree Access Decitabine as “bridge therapy” to a MUD transplant in relapsed AML postautologous stem cell transplantation Celalettin Ustun, Celalettin Ustun Medical College of Georgia, Section of Hematology-Oncology, Augusta, GeorgiaSearch for more papers by this authorAbhishek Kalla, Abhishek Kalla Medical College of Georgia, Department of Medicine, Augusta, GeorgiaSearch for more papers by this authorStephanie Farrow, Stephanie Farrow Medical College of Georgia, Section of Hematology-Oncology, Augusta, GeorgiaSearch for more papers by this authorDavid L. Deremer, David L. Deremer Medical College of Georgia, University of Georgia College of Pharmacy, Augusta, GeorgiaSearch for more papers by this authorAnand Jillella, Anand Jillella Medical College of Georgia, Section of Hematology-Oncology, Augusta, GeorgiaSearch for more papers by this author Celalettin Ustun, Celalettin Ustun Medical College of Georgia, Section of Hematology-Oncology, Augusta, GeorgiaSearch for more papers by this authorAbhishek Kalla, Abhishek Kalla Medical College of Georgia, Department of Medicine, Augusta, GeorgiaSearch for more papers by this authorStephanie Farrow, Stephanie Farrow Medical College of Georgia, Section of Hematology-Oncology, Augusta, GeorgiaSearch for more papers by this authorDavid L. Deremer, David L. Deremer Medical College of Georgia, University of Georgia College of Pharmacy, Augusta, GeorgiaSearch for more papers by this authorAnand Jillella, Anand Jillella Medical College of Georgia, Section of Hematology-Oncology, Augusta, GeorgiaSearch for more papers by this author First published: 19 August 2008 https://doi.org/10.1002/ajh.21267Citations: 6AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Kantarjian H,Issa JP,Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006; 106: 1794– 1803. 2 Silva LD dM,Kantarjian H,Champlin R, et al. Outcome of allogeneic stem cell transplantation after hypomethylating therapy with 2′-deoxy-5 azacytidine for patients with myelodysplastic syndrome. Blood 2007; 110: 1468a. 3 Lubbert MRB,Schmid M,Knipp S, et al. Continued low-dose decitabine (DAC) is an active first-line treatment of older AML patients: First results of a multicenter Phase II study. Blood 2005; 106: 1852a. 4 Ravandi FIJ,Faderl S,Garcia-Manero G, et al. Randomized study of decitabine versus observation or continued cytotoxic chemotherapy in patients with intermediate and poor risk acute myeloid leukemia in first or subsequent complete remission. Blood 2007; 110: 2859a. 5 Graef T,Kuendgen A,Fenk R, et al. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res 2007; 31: 257– 259. 6 Rossetti JM,Shadduck RK,Chandana Thatikonda C, et al. Low-dose azacitidine for relapse of MDS/AML after unrelated donor peripheral blood stem cell transplantation. Blood 2007; 110: 5034a. 7 Cashen AF,Devine H,DiPersio J. Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine. Am J Hematol 2006; 81: 543– 545. 8 Estey E. Treatment of refractory AML. Leukemia 1996; 10: 932– 936. 9 Lee S,Tallman MS,Oken MM, et al. Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Eastern Cooperative Oncology Group. Leukemia 2000; 14: 1345– 1348. 10 Levy V,Marjanovic Z,Vekhoff A, et al. Relapse after autologous hematopoietic stem cell transplantation in acute myeloid leukemia, a single center experience over 13 years. Am J Hematol 2000; 64: 232– 233. 11 Breems DA,Van Putten WL,Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23: 1969– 1978. 12 Breems DA,Boogaerts MA,Dekker AW, et al. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: A prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol 2005; 128: 59– 65. 13 Bug G,Atta J,Klein SA, et al. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation. Ann Hematol 2005; 84: 748– 754. 14 Diaconescu R,Flowers CR,Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550– 1558. Citing Literature Volume83, Issue10October 2008Pages 825-827 ReferencesRelatedInformation